Application of anti-angiogenic therapy in non-small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 973-979, 2018.
Article
em Zh
| WPRIM
| ID: wpr-706867
Biblioteca responsável:
WPRO
ABSTRACT
Non-small cell lung cancer (NSCLC) accounts for 85% of total cases of lung cancer, which has the highest incidence and mor-tality in China. Most patients with lung cancer present with advanced stage disease at the time of diagnosis. With the limited develop-ment of cytotoxic chemotherapy for NSCLC therapy, median overall survival in patients receiving platinum-based doublet chemothera-py has been less than one year in several trials. To date, anti-angiogenesis agents combined with chemotherapy, small molecule tyro-sine kinase inhibitors (TKI) and immune checkpoint inhibitors were commonly applied in NSCLC instead of purely chemotherapy, which makes a great breakthrough in NSCLC therapy. This review summarizes and discusses the application of anti-angiogenic therapy in ad-vanced NSCLC.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Clinical Oncology
Ano de publicação:
2018
Tipo de documento:
Article